Lilly Ventures has its roots in the scientific tradition of Eli Lilly and Company. Our investment philosophy drives us to seek great companies with compelling life science innovations.
Our collaborative partnership leverages the collective experience, deep expertise, and networks of our investment professionals for the benefit of our portfolio companies.
GlobeImmune, Inc. and Celgene Corporation (NASDAQ: CELG) today announced a worldwide strategic collaboration focused on the discovery, development and commercialization of multiple product candidates based on powerful, targeted molecular immunotherapy for the treatment of cancer.
Hydra Biosciences, Inc., a biotech company developing novel ion channel drugs, today announced that research published by Hydra Biosciences scientists and collaborators at Yale University for the first time identified the ion channel TRPA1 as playing an essential role in allergic asthma and demonstrated that Hydra’s TRPA1 antagonist HC-030031 effectively treated allergic asthma in mice.
Cylene Pharmaceuticals, Inc., announced today that it will present major advances in the development of their first-in-class, CK2 inhibitor CX-4945 at the 2009 BIO International Convention on Wednesday, May 20th at 4:40 pm.
When Aileron announced its $40 million venture round earlier this month, the press zeroed in closely on the four big pharma venture arms that were crowding in to support the developer. The CEO says the company is on to a brand new way to develop therapeutics and there are clearly a lot of major players who want to have a front seat as researchers put a breakthrough theory to the test.
FORMA Therapeutics announced today that Kenneth W. Bair, Ph.D., has been appointed as Senior Vice President and Head of Research and Development.
Viamet Pharmaceuticals, Inc. announced today that it has secured $18 million in a Series B financing to accelerate the development of its novel metalloenzyme inhibitors and to advance its Metallophile™ Technology platform.
Hydra Biosciences today announced that they have entered into an agreement with Cubist Pharmaceuticals, Inc.
Receptos, Inc., a privately held biopharmaceutical company, announced the closing of a two-tranche $25 million Series A financing.
FORMA Therapeutics today announced that it has closed on a Series B financing that raised a total of $25.5 million.
HemaQuest Pharmaceuticals presented data from new preclinical studies and early results from clinical trials of its lead drug candidate, HQK-1001, in sickle cell disease and beta thalassemia at the annual meeting of the American Society of Hematology in New Orleans.
Silence Therapeutics plc (“the Company”) (AIM: SLN) and Intradigm Corporation announce that the companies have completed their merger to form a leading company in the field of RNAi (RNA interference).
Viamet Pharmaceuticals, Inc., a pharmaceutical company developing novel, best in class metalloenzyme inhibitors, announced today that William Moore, Ph.D. has joined the company as Chief Scientific Officer.
Early data show strong correlation between florbetapir PET imaging and Alzheimer’s disease beta-amyloid pathology
GlobeImmune Inc. announced Phase 2b data for GI-5005, the Company’s investigational Tarmogen® product for hepatitis C virus (HCV) infection, correlating GI-5005 treatment response rate and IL-28 B genotype in patients with chronic HCV infection.
HemaQuest Pharmaceuticals, a clinical stage biotechnology company developing compounds to treat sickle cell disease, beta thalassemia and EBV-related cancers, announced today the closing of a $12M Series B financing led by new investor, Aberdare Ventures.
Remember the old "suggestion box" that hit up workers or customers for new ideas? That concept has matured in the 21st century. It's now known as crowdsourcing.
R&D Spotlight describes Stapeled Peptides as a revolutionary new class fo drugs to address thousands of currently undruggable targets.
Gilead Science and CGI announce the signing of a Definitive Agreement whereby Gilead will acquire CGI.
